COVID-19 in India: Over 27,000 cases reported in 24 hours; 8.2 lakh infections so far
India recorded 519 deaths during the last 24 hours, taking the total number of death count to 22,123.
India's COVID-19 tally has reached 8,20,916 with the biggest single-day increase of 27,114, according to the latest data from the Union Health Ministry on Saturday morning. The country recorded 519 deaths during the period, taking the total number of death count to 22,123.
The coronavirus case tally in India surpassed the eight-lakh-mark on Friday in just four days after the number of infections in the country had reached seven lakh. India is the third worst-hit country by the COVID-19 pandemic. Only the US and Brazil are ahead of India in terms of total coronavirus infections.
#IndiaFightsCorona:#COVID19 India UPDATE:— #IndiaFightsCorona (@COVIDNewsByMIB) July 11, 2020
▪️ Total Cases - 820,916
▪️ Active Cases - 283,407
▪️ Cured/Discharged- 515,385
▪️ Deaths - 22,123
▪️ Migrated - 1
as on July 11, 2020 till 8:00 AM pic.twitter.com/EqTKmXtwt0
PSORIASIS INJECTION 'APPROVED FOR COVID-19 TREATMENT'
This comes as India's drug regulator approved Itolizumab -- a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress -- PTI reported on Friday citing officials.
Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V.G. Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome,” an official told PTI.
"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said. Written informed consent of each patient is required before the use of this drug, he said.